Machine-Learning Drug Discovery
Insitro
GALDERA LABS CAPITAL — LA JOLLA, CA
Capital at the frontier of biological computation.
We invest in companies applying machine learning, computational biology, and genomic engineering to compress the timeline between scientific discovery and therapeutic impact. Our partners have worked at the bench and in the clinic. We evaluate science because we understand it.
$140M
Assets Under Management
2
Funds Deployed
8
Portfolio Companies
2017
Founded, La Jolla CA
Our Thesis
Where computation meets clinical urgency.
Drug discovery is being rewritten by computation. Platforms that model biology at the level of cells, proteins, and genetic circuits are compressing the experimental cycle from years to months. Galdera invests at the earliest stages of this transition — when the science is proven but the company is not yet formed around it.
Platform Science
We back platforms that generate repeatable discovery — not one-shot therapeutics, but engines that can produce many.
Computational Rigor
Our partners have run computational programs in pharma. We evaluate models, training sets, and validation protocols, not decks.
Translational Readiness
Scientific novelty alone is insufficient. We assess the path from computational hit to first clinical evidence.